Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) have been given an average rating of “Moderate Buy” by the six ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $11.00.

A number of research analysts recently weighed in on EVAX shares. Lake Street Capital dropped their price objective on Evaxion A/S from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Monday, March 9th. JonesTrading started coverage on Evaxion A/S in a report on Tuesday, March 10th. They set a “buy” rating and a $10.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evaxion A/S in a report on Friday, January 9th. Wall Street Zen lowered Evaxion A/S from a “buy” rating to a “hold” rating in a report on Sunday, March 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of Evaxion A/S in a report on Friday.

Evaxion A/S Trading Down 5.2%

NASDAQ:EVAX opened at $4.03 on Friday. The firm has a market cap of $33.61 million, a P/E ratio of -3.05 and a beta of 0.19. The company has a current ratio of 5.85, a quick ratio of 5.85 and a debt-to-equity ratio of 0.41. The stock’s 50 day simple moving average is $3.74 and its 200-day simple moving average is $4.75. Evaxion A/S has a 12-month low of $1.42 and a 12-month high of $12.15.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. SmartHarvest Portfolios LLC acquired a new position in Evaxion A/S during the fourth quarter worth $72,000. Northwestern Mutual Wealth Management Co. acquired a new position in Evaxion A/S during the fourth quarter worth $38,000. Finally, Wesbanco Bank Inc. acquired a new position in Evaxion A/S during the fourth quarter worth $48,000. Institutional investors and hedge funds own 11.04% of the company’s stock.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.